Literature DB >> 20957647

Fine-mapping reveals novel alternative splicing of the dopamine transporter.

Michael E Talkowski1, Kathleen L McCann, Michael Chen, Lora McClain, Mikhil Bamne, Joel Wood, Kodavali V Chowdari, Annie Watson, Konasale M Prasad, George Kirov, Lyudmilla Georgieva, Draga Toncheva, Hader Mansour, David A Lewis, Michael Owen, Michael O'Donovan, Panagiotis Papasaikas, Patrick Sullivan, Douglas Ruderfer, Jeffrey K Yao, Sherry Leonard, Pramod Thomas, Fabio Miyajima, John Quinn, A Javier Lopez, Vishwajit L Nimgaonkar.   

Abstract

The dopamine transporter gene (SLC6A3, DAT) has been implicated in the pathogenesis of numerous psychiatric and neurodevelopmental disorders, including schizophrenia (SZ). We previously detected association between SZ and intronic SLC6A3 variants that replicated in two independent Caucasian samples, but had no obvious function. In follow-up analyses, we sequenced the coding and intronic regions of SLC6A3 to identify complete linkage disequilibrium patterns of common variations. We genotyped 78 polymorphisms, narrowing the potentially causal region to two correlated clusters of associated SNPs localized predominantly to introns 3 and 4. Our computational analysis of these intronic regions predicted a novel cassette exon within intron 3, designated E3b, which is conserved among primates. We confirmed alternative splicing of E3b in post-mortem human substantia nigra (SN). As E3b introduces multiple in-frame stop codons, the SLC6A3 open reading frame is truncated and the spliced product may undergo nonsense mediated decay. Thus, factors that increase E3b splicing could reduce the amount of unspliced product available for translation. Observations consistent with this prediction were made using cellular assays and in post-mortem human SN. In mini-gene constructs, the extent of splicing is also influenced by at least two common haplotypes, so the alternative splicing was evaluated in relation to SZ risk. Meta-analyses across genome-wide association studies did not support the initial associations and further post-mortem studies did not suggest case-control differences in splicing. These studies do not provide a compelling link to schizophrenia. However, the impact of the alternative splicing on other neuropsychiatric disorders should be investigated. © 2010 Wiley-Liss, Inc.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20957647      PMCID: PMC4575812          DOI: 10.1002/ajmg.b.31125

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  78 in total

Review 1.  PET studies of brain monoamine transporters.

Authors:  A Laakso; J Hietala
Journal:  Curr Pharm Des       Date:  2000-11       Impact factor: 3.116

2.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

Authors:  M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

Review 3.  Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells.

Authors:  Fabrice Lejeune; Lynne E Maquat
Journal:  Curr Opin Cell Biol       Date:  2005-06       Impact factor: 8.382

4.  Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease.

Authors:  Samir N Kelada; Paola Costa-Mallen; Harvey Checkoway; Christopher S Carlson; Terri-Smith Weller; Phillip D Swanson; Gary M Franklin; W T Longstreth; Zahra Afsharinejad; Lucio G Costa
Journal:  Pharmacogenet Genomics       Date:  2005-09       Impact factor: 2.089

5.  Enhanced cleavage of an atypical intron of dopamine D3-receptor pre-mRNA in chronic schizophrenia.

Authors:  C Schmauss
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

6.  Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3' non-coding polymorphic region of the human dopamine transporter (DAT1) gene.

Authors:  Satoshi Fuke; Noboru Sasagawa; Shoichi Ishiura
Journal:  J Biochem       Date:  2005-02       Impact factor: 3.387

7.  PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain.

Authors:  L Farde; C Halldin; L Müller; T Suhara; P Karlsson; H Hall
Journal:  Synapse       Date:  1994-02       Impact factor: 2.562

8.  Common variants on chromosome 6p22.1 are associated with schizophrenia.

Authors:  Jianxin Shi; Douglas F Levinson; Jubao Duan; Alan R Sanders; Yonglan Zheng; Itsik Pe'er; Frank Dudbridge; Peter A Holmans; Alice S Whittemore; Bryan J Mowry; Ann Olincy; Farooq Amin; C Robert Cloninger; Jeremy M Silverman; Nancy G Buccola; William F Byerley; Donald W Black; Raymond R Crowe; Jorge R Oksenberg; Daniel B Mirel; Kenneth S Kendler; Robert Freedman; Pablo V Gejman
Journal:  Nature       Date:  2009-07-01       Impact factor: 49.962

9.  Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia.

Authors:  Karmen K Yoder; Gary D Hutchins; Evan D Morris; Allison Brashear; Chunzi Wang; Anantha Shekhar
Journal:  Schizophr Res       Date:  2004-12-01       Impact factor: 4.939

10.  Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment.

Authors:  Colin O'Gara; John Stapleton; Gay Sutherland; Camila Guindalini; Ben Neale; Gerome Breen; David Ball
Journal:  Pharmacogenet Genomics       Date:  2007-01       Impact factor: 2.089

View more
  5 in total

1.  Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Natalie Kaplan; Aya Vituri; Amos D Korczyn; Oren S Cohen; Rivka Inzelberg; Gilad Yahalom; Evgenia Kozlova; Roni Milgrom; Yael Laitman; Eitan Friedman; Saharon Rosset; Sharon Hassin-Baer
Journal:  J Mol Neurosci       Date:  2014-03-15       Impact factor: 3.444

2.  Association study of neuregulin-1 gene polymorphisms in a North Indian schizophrenia sample.

Authors:  Prachi Kukshal; Triptish Bhatia; A M Bhagwat; Raquel E Gur; Ruben C Gur; Smita N Deshpande; Vishwajit L Nimgaonkar; B K Thelma
Journal:  Schizophr Res       Date:  2013-01-26       Impact factor: 4.939

3.  Allelic variant in SLC6A3 rs393795 affects cerebral regional homogeneity and gait dysfunction in patients with Parkinson's disease.

Authors:  Lina Wang; Yongsheng Yuan; Jianwei Wang; Yuting Shen; Yan Zhi; Junyi Li; Min Wang; Kezhong Zhang
Journal:  PeerJ       Date:  2019-11-04       Impact factor: 2.984

4.  Persistent infection by HSV-1 is associated with changes in functional architecture of iPSC-derived neurons and brain activation patterns underlying working memory performance.

Authors:  Leonardo D'Aiuto; Konasale M Prasad; Catherine H Upton; Luigi Viggiano; Jadranka Milosevic; Giorgio Raimondi; Lora McClain; Kodavali Chowdari; Jay Tischfield; Michael Sheldon; Jennifer C Moore; Robert H Yolken; Paul R Kinchington; Vishwajit L Nimgaonkar
Journal:  Schizophr Bull       Date:  2014-03-12       Impact factor: 9.306

5.  SVA retrotransposons as modulators of gene expression.

Authors:  John P Quinn; Vivien J Bubb
Journal:  Mob Genet Elements       Date:  2014-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.